Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) (353369)

From US Department of Health & Human Services: National Institutes of Health (NIH)

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.

Type of Support

Overview

The grant program aims to fund efficacy studies in established rare disease preclinical models to demonstrate that a proposed therapeutic agent is ready for further development. It supports studies on therapeutic agents, including small molecules, biologics, or biotechnology-derived products, focusing on preclinical efficacy along with pharmacodynamic and pharmacokinetic studies. The objective is to advance therapeutic development for various rare diseases, encouraging projects to reach a stage that would attract further investment for full Investigational New Drug (IND) application development or progression to clinical trials, especially in cases of repurposing or repositioning existing treatments.

Eligibility

Organization's Location
esse ut, amet in, do tempor, adipisicing nisi, cupidatat deserunt, cillum ullamco
Program Location
consectetur velit nostrud sint commodo officia officia fugiat sit velit
Organization Type
up to 275k

Submission

Schedule
Step 1: ullamco amet dolore
Application deadline
Dec 25, 2024
Step 2: nostrud elit (do aliqua)

Similar grants

Sign up to view more grants
Already have an account?Log in